Physician profile
Muhammad U Anwer
NPI 1194991992
$1,616.78
in general payments reported to CMS, 2019-2025
16 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2024: $235 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527 · Travel and Lodging: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.14 |
| Travel and Lodging | $365.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $606.60 | 2019 | |
| Intuitive Surgical, INC. | $365.55 | 2025 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals Lp | $93.24 | 2024-2025 | Tezspire, Airsupra |
| Genzyme Corporation | $81.86 | 2024-2025 | |
| Getinge USA Sales, LLC | $79.49 | 2019 | |
| Insmed, INC. | $58.30 | 2024-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $38.00 | 2019 | |
| Merck Sharp & Dohme LLC | $25.84 | 2025 | Zerbaxa |
| Abbvie INC. | $23.15 | 2024 | |
| Glaxosmithkline, LLC. | $23.11 | 2025 | Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $22.41 | 2025 | Dupixent |
| Verona Pharma, INC. | $21.28 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2025 | Glassia |
| Paratek Pharmaceuticals, INC. | $17.46 | 2025 | Nuzyra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.78 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Anwer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.